Through the Looking Glass:
Seeing a Better Future in Crohn’s Disease

Non-Invasive Imaging in Crohn’s Disease Clinical Case Convo

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE

This activity is supported by an educational grant from Lilly.

Program Overview

While historically the goals of Crohn’s disease treatment were limited to symptomatic clinical remission, the availability of disease-modifying therapies have now extended treatment goals to include that of sustained deep remission. Coupled with these paradigm shifts were the introduction of newer management strategies, including the early introduction of highly effective therapy, a tight and frequent control of mucosal inflammation, and adjustments in treatment based on endpoints and assessments. This clinical case conversation will focus on non-invasive imaging techniques and their role in diagnosing and monitoring treatment response in patients with Crohn’s disease.

Faculty

Aline Charabaty, MD, FACG, AGAF (program chair)
Associate Professor of Medicine
Johns Hopkins School of Medicine
Medical Director of the Division of Gastroenterology and Hepatology
Clinical Director of the IBD Center at Johns Hopkins
Sibley Memorial Hospital
Washington, D.C.

Michael Todd Dolinger, MD MBA (guest faculty)
Assistant Professor of Pediatrics
Associate Pediatric Gastroenterology Fellowship Program Director
Division of Pediatric Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY

Target Audience

The target audience for this program is IBD specialists, gastroenterologists, gastroenterology fellows and trainees, nurse practitioners and physician’s assistants who care for patients with Crohn’s disease. Additionally, nurses, specialty pharmacists and other healthcare practitioners involved or interested in the care of patients with Crohn’s disease.

Learning Objectives

After completing this activity series, learners should be better able to identify appropriate methods for assessing transmural inflammation.

Disclosure of Relevant Financial Relationships

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

 

  • Aline Charabaty, MD, FACG, AGAF
    Consultant & Advisor: AbbVie, Janssen, Eli Lilly, Pfizer, Takeda

    Michael Dolinger, MD, MBA
    Consultant, Advisor, & Speaker: BMS, Johnson & Johnson, Neurologica Corp, a subsidiary of Samsung Electronics Co Ltd., Pfizer

Joint Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

Release date: November 11, 2024
Expiration date: November 11, 2025
Estimated time to complete activity: 30 minutes